Quantcast
Last updated on April 24, 2014 at 0:13 EDT

Latest IgA nephropathy Stories

2014-03-12 20:24:20

HAYWARD, Calif., March 12, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013. Fourth Quarter and Fiscal Year 2013 Financial Results: Net loss for the fourth quarter and year ended December 31, 2013 was $9.2 million and $30.9 million, respectively. Operating expense for the year ended December 31, 2013 was $28.2 million as compared to $55.9 million for...

2014-01-13 04:20:59

STOCKHOLM, January 13, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces it has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon(R) (http://www.nefigan.net). Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess the efficacy and safety...

2014-01-10 08:23:12

Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif., Jan. 10, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below)....

2013-10-29 16:26:18

HAYWARD, Calif., Oct. 29, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results, clinical and regulatory update for the quarter ended September 30, 2013. Third Quarter 2013 Financial Results: Net loss for the third quarter of 2013 decreased to $5.8 million from $12.0 million, and loss per basic and diluted share decreased to $0.30 from $1.38, as compared to the same quarter in 2012. Net loss for the nine months ended September 30,...

2013-09-25 08:30:03

HAYWARD, Calif., Sept. 25, 2013 /PRNewswire/ -- Anthera Pharmaceuticals (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that emerging data from its Phase 2b PEARL-SC study and subsequent Open-Label Extension study will be presented by Dr. Richard Furie at the 2013 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals...

2013-07-30 16:25:29

HAYWARD, Calif., July 30, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended June 30, 2013. Second Quarter 2013 Financial Results: Loss from operations decreased in the second quarter of 2013 to $7.0 million from $16.7 million in the second quarter of 2012, and to $13.9 million for the six months ended June 30, 2013 compared to $36.7 million for the comparable period in 2012. The...

2013-06-24 08:28:22

HAYWARD, Calif., June 24, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with autoimmune disorders, today announced it has initiated the BRIGHT-SC Phase 2 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of IgA nephropathy. IgA nephropathy is a chronic autoimmune renal disease characterized by proteinuria and progression to end stage renal...

2012-12-18 04:20:54

STOCKHOLM, December 18, 2012 /PRNewswire/ -- Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon(R)(Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease. Nefecon is an enteric formulation of a locally acting corticosteroid that down-regulates the inflammatory process in the kidneys through suppression of the gastrointestinal immune system. The study is a multi-center,...

2012-11-28 08:30:09

HAYWARD, Calif., Nov. 28, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study was presented in a poster at the 2012 Asian Lupus Summit. The poster entitled "The Subcutaneous BAFF Inhibitor, Blisibimod, Significantly Reduces Proteinuria in Subjects with Moderate-to-Severe Systemic Lupus...

2012-10-31 03:20:45

STOCKHOLM, October 31, 2012 /PRNewswire/ -- Pharmalink AB, a Swedish specialty pharma company, today announces it has entered into a contract with Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry for the manufacturing of Nefecon(R), Pharmalink's lead product. Nefecon is being developed as the first on-label medication specifically aimed at addressing the underlying pathology of progressive IgA nephropathy,...